Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of purchasers of CytRx Corporation (NASDAQ:CYTR) common stock during the period between November 22, 2013 and March 13, 2014, inclusive (the “Class Period”). CytRx Corporation (NASDAQ:CYTR) stock performance was 0.00% in last session and finished the day at $4.08. Traded volume was 3.57 million shares in the last session and the average volume of the stock remained 2.77 million shares. The beta of the stock remained 1.49. CytRx Corporation (NASDAQ:CYTR) insider ownership is 8.50%.

Equities research analysts at MLV & Co. cut their price target on shares of Synta Pharmaceuticals Corp. (NASDAQ:SNTA) from $10.00 to $6.00 in a research note issued to investors on Thursday, Analyst Ratings Network reports. The firm currently has a “buy” rating on the stock. MLV & Co.‘s target price indicates a potential upside of 36.99% from the company’s current price. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) rose 8.28% to $4.71 yesterday on volume of 3.39 million shares. The intra-day range of the stock was $4.34 – $4.76. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) has a market capitalization of 361.88 million.

Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) announced that it has filed patent infringement lawsuits against Gilead Sciences, Inc. (NASDAQ:GILD) and/or certain of its subsidiaries in each of three countries – France, Germany and the United Kingdom. Idenix Pharmaceuticals Inc. (NASDAQ:IDIX)’s stock on March 18, 2014 reported a higher of 8.46% to the closing price of $7.82. Its fifty two weeks range is $2.93 – $9.32. The total market capitalization recorded 1.05 billion. The overall volume in the last trading session was 2.51 million shares. In its share capital, Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) has 133.97 million outstanding shares.

CEL-SCI Corporation (NYSEMKT:CVM) 0n march 4 announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection) has activated its first U.S. On Tuesday, shares of CEL-SCI Corporation (NYSEMKT:CVM) advanced 7.86% to close the day at $1.51. Company return on investment (ROI) is -253.80% and its monthly performance is recorded as 27.97%. CEL-SCI Corporation (NYSEMKT:CVM) quarterly revenue growth is 109.72%.